Oncolytic adenoviruses for the treatment of brain tumors

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 5, 2010, Pages 530-537

  Gomez Manzano, Candelaria ^a   Fueyo, Juan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; IRINOTECAN; MICRORNA; ONCOLYTIC ADENOVIRUS; PF 1367338; RAPAMYCIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VELIPARIB;

3' UNTRANSLATED REGION; AUTOPHAGY; BRAIN TUMOR; CANCER RADIOTHERAPY; CELL DEATH; CHEMOSENSITIZATION; CLINICAL TRIAL; DNA REPAIR; GENOME; GLIOMA; GLIOMA CELL; HEAD AND NECK CANCER; HUMAN; NASOPHARYNX CANCER; NONHUMAN; ONCOGENE; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; TUMOR SUPPRESSOR GENE; VIROTHERAPY; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENOVIRIDAE; BRAIN NEOPLASMS; HUMANS; MICRORNAS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

ADENOVIRIDAE;

EID: 77957740491     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Liu TC, Kirn D: Systemic efficacy with oncolytic virus therapeutics: Clinical proof-of-concept and future directions. Cancer Res (2007) 67 (2):429-432.
2. Whyte P, Williamson NM, Harlow E: Cellular targets for transformation by the adenovirus E1A proteins. Cell (1989) 56 (1):67-75.
3. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, Shi YX, Levin VA, Yung WK, Kyritsis AP: A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene (2000) 19 (1):2-12. • First description of the delta-24 adenovirus and evidence of the Rb-dependent tumor selectivity.
4. Suzuki K, Fueyo J, Krasnykh V, Reynolds PN, Curiel DT, Alemany R: A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res (2001) 7 (1):120-126. • First report of delta-24-RGD, a tropism-enhanced oncolytic adenovirus that is currently in clinical trial for the treatment of patients with malignant gliomas.
5. Ito H, Aoki H, Kuhnel F, Kondo Y, Kubicka S, Wirth T, Iwado E, Iwamaru A, Fujiwara K, Hess KR, Lang FF et al: Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Natl Cancer Inst (2006) 98 (9):625-636. •• Demonstrates for the first time that cells infected with replication competent adenoviruses undergo autophagy.
6. Mizushima N, Levine B, Cuervo AM, Klionsky DJ: Autophagy fights disease through cellular self-digestion. Nature (2008) 451 (7182):1069-1075.
7. Kudchodkar SB, Levine B: Viruses and autophagy. Rev Med Virol (2009) 19 (6):359-378.
8. Shoji-Kawata S, Levine B: Autophagy, antiviral immunity, and viral countermeasures. Biochim Biophys Acta (2009) 1793 (9):1478-1484.
9. Orvedahl A, Alexander D, Tallóczy Z, Sun Q, Wei Y, Zhang W, Burns D, Leib DA, Levine B: HSV-1 ICP34.5 confers neurovirulence by targeting the Beclin 1 autophagy protein. Cell Host Microbe (2007) 1 (1):23-35.
10. Kirkegaard K: Subversion of the cellular autophagy pathway by viruses. Curr Top Microbiol Immunol (2009) 335:323-333.
11. Wileman T: Aggresomes and autophagy generate sites for virus replication. Science (2006) 312 (5775):875-878. •• Proposes that certain viruses exploit the triggering of autophagy for their own benefit and thus autophagosomes are transformed into 'viral factories'.
12. Lee YR, Lei HY, Liu MT, Wang JR, Chen SH, Jiang-Shieh YF, Lin YS, Yeh TM, Liu CC, Liu HS: Autophagic machinery activated by dengue virus enhances virus replication. Virology (2008) 374 (2):240-248.
13. Yokoyama T, Iwado E, Kondo Y, Aoki H, Hayashi Y, Georgescu MM, Sawaya R, Hess KR, Mills GB, Kawamura H, Hashimoto Y et al: Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells. Gene Ther (2008) 15 (17):1233-1239.
14. Bergmann A: Autophagy and cell death: No longer at odds. Cell (2007) 131 (6):1032-1034.
15. Jiang H, Gomez-Manzano C, Aoki H, Alonso MM, Kondo S, McCormick F, Xu J, Kondo Y, Bekele BN, Colman H, Lang FF et al: Examination of the therapeutic potential of delta-24-RGD in brain tumor stem cells: Role of autophagic cell death. J Natl Cancer Inst (2007) 99 (18):1410-1414. •• First study describing that infection of cells with oncolytic adenoviruses results in increased levels of the autophagy-related protein complex Atg5/Atg12.
16. Dean M, Fojo T, Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer (2005) 5 (4):275-284.
17. Ogawa M, Yoshimori T, Suzuki T, Sagara H, Mizushima N, Sasakawa C: Escape of intracellular Shigella from autophagy. Science (2005) 307 (5710):727-731. • Demonstrated that bacteria can target the autophagy related protein Atg5 to manipulate autophagy.
18. Bell BD, Leverrier S, Weist BM, Newton RH, Arechiga AF, Luhrs KA, Morrissette NS, Walsh CM: FADD and caspase-8 control the outcome of autophagic signaling in proliferating T cells. Proc Natl Acad Sci USA (2008) 105 (43):16677-16682.
19. Yousefi S, Perozzo R, Schmid I, Ziemiecki A, Schaffner T, Scapozza L, Brunner T, Simon HU: Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. Nat Cell Biol (2006) 8 (10):1124-1132.
20. Reef S, Zalckvar E, Shifman O, Bialik S, Sabanay H, Oren M, Kimchi A: A short mitochondrial form of p19ARF induces autophagy and caspase-independent cell death. Mol Cell (2006) 22 (4):463-475.
21. Jung CH, Ro SH, Cao J, Otto NM, Kim DH: mTOR regulation of autophagy. FEBS Lett (2010) 584 (7):1287-1295.
22. Rajecki M, af Hällström T, Hakkarainen T, Nokisalmi P, Hautaniemi S, Nieminen AI, Tenhunen M, Rantanen V, Desmond RA, Chen DT, Guse K et al: Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation. Int J Cancer (2009) 125 (10):2441-2449.
23. Tyler MA, Ulasov IV, Lesniak MS: Cancer cell death by design: Apoptosis, autophagy and glioma virotherapy. Autophagy (2009) 5 (6):856-857.
24. Ulasov IV, Sonabend AM, Nandi S, Khramtsov A, Han Y, Lesniak MS: Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo. Br J Cancer (2009) 100 (7):1154-1164.
25. Baird SK, Aerts JL, Eddaoudi A, Lockley M, Lemoine NR, McNeish IA: Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer. Oncogene (2008) 27 (22):3081-3090.
26. Jiang H, White EJ, Gomez-Manzano C, Fueyo J: Adenovirus's last trick: You say lysis, we say autophagy. Autophagy (2008) 4 (1):118-120.
27. Alonso MM, Jiang H, Yokoyama T, Xu J, Bekele NB, Lang FF, Kondo S, Gomez-Manzano C, Fueyo J: Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. Mol Ther (2008) 16 (3):487-493. •• Provides evidence that a combination of oncolytic adenoviruses with autophagy inducers for the treatment of cancer results in enhanced potency of the replication-competent adenoviruses.
28. Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 6 (11):857-866.
29. Bell JC, Kirn D: MicroRNAs fine-tune oncolytic viruses. Nat Biotechnol (2008) 26 (12):1346-1348.
30. Ivanovska I, Cleary MA: Combinatorial microRNAs: Working together to make a difference. Cell Cycle (2008) 7 (20):3137-3142.
31. Xu S, Witmer PD, Lumayag S, Kovacs B, Valle D: MicroRNA (miRNA) transcriptome of mouse retina and identification of a sensory organ-specific miRNA cluster. J Biol Chem (2007) 282 (34):25053-25066.
32. Obbard DJ, Gordon KH, Buck AH, Jiggins FM: The evolution of RNAi as a defence against viruses and transposable elements. Philos Trans R Soc Lond B Biol Sci (2009) 364 (1513):99-115.
33. Deng S, Calin GA, Croce CM, Coukos G, Zhang L: Mechanisms of microRNA deregulation in human cancer. Cell Cycle (2008) 7 (17):2643-2646.
34. Brown BD, Venneri MA, Zingale A, Sergi Sergi L, Naldini L: Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat Med (2006) 12 (5):585-591. •• First report of the use of miRNA to obtain tissue-specific transduction of exogenous genes using viral vectors.
35. Brown BD, Gentner B, Cantore A, Colleoni S, Amendola M, Zingale A, Baccarini A, Lazzari G, Galli C, Naldini L: Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol (2007) 25 (12):1457-1467.
36. Kelly EJ, Hadac EM, Greiner S, Russell SJ: Engineering microRNA responsiveness to decrease virus pathogenicity. Nat Med (2008) 14 (11):1278-1283.
37. Cawood R, Chen HH, Carroll F, Bazan-Peregrino M, van Rooijen N, Seymour LW: Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells. PLoS Pathog (2009) 5(5):e1000440.
38. Ylosmaki E, Hakkarainen T, Hemminki A, Visakorpi T, Andino R, Saksela K: Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific microRNA. J Virol (2008) 82 (22):11009-11015.
39. Edge RE, Falls TJ, Brown CW, Lichty BD, Atkins H, Bell JC: A let-7 microRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. Mol Ther (2008) 16 (8):1437-1443.
40. Liu TC, Galanis E, Kirn D: Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress. Nat Clin Pract Oncol (2007) 4 (2):101-117.
41. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (1996) 274 (5286):373-376. •• First communication about the possibility of targeting tumor suppressor pathways to develop tumor-selective oncolytic adenoviruses.
42. Garber K: China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst (2006) 98 (5):298-300.
43. Xia ZJ, Chang JH, Zhang L, Jiang WQ, Guan ZZ, Liu JW, Zhang Y, Hu XH, Wu GH, Wang HQ, Chen ZC et al: Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatinbased chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai Zheng (2004) 23 (12):1666-1670.
44. Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T, Landers S, Maples P, Romel L, Randlev B, Reid T et al: Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. Cancer Res (2000) 60 (22):6359-6366.
45. Gomez-Manzano C, Alonso MM, Yung WK, McCormick F, Curiel DT, Lang FF, Jiang H, Bekele BN, Zhou X, Alemany R, Fueyo J: Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res (2006) 12 (2):556-562.
46. Chow KC, Pearson GD: Adenovirus infection elevates levels of cellular topoisomerase I. Proc Natl Acad Sci USA (1985) 82 (8):2247-2251.
47. 6-methylguanine- DNA methyltransferase gene by transcriptional coactivators cAMP response element-binding protein-binding protein and p300. J Biol Chem (2000) 275 (44):34197-34204.
48. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 352 (10):997-1003.
49. Jiang H, Alonso MM, Gomez-Manzano C, Piao Y, Fueyo J: Oncolytic viruses and DNA-repair machinery: Overcoming chemoresistance of gliomas. Expert Rev Anticancer Ther (2006) 6 (11):1585-1592.
50. Ratnam K, Low JA: Current development of clinical inhibitors of poly (ADP-ribose) polymerase in oncology. Clin Cancer Res (2007) 13 (5):1383-1388.
51. 6-methylguanine-DNA methyltransferase promoter. Cancer Res (2007) 67 (24):11499-11504. •• Demonstrated that infection of cancer cells with oncolytic adenoviruses results in the silencing of the MGMT promoter and enhances chemosensitivity.